Drug Profile
Pancrelipase (Ultrase) delayed-release - AbbVie
Alternative Names: UltraseMT; Ultresa/UltraseLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Eurand
- Developer AbbVie
- Class Pancreatic enzymes
- Mechanism of Action Pancrelipase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pancreatic disorders
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie